Fig. 4
Effect of amygdalin, sorafenib, and their combination on cell cycle. Flow cytometry analysis of (A) HepG2; (C) WI-38 cells after treatment with IC50/2 concentration for each drug for 48 h. (B, D) Quantitative data analysis for the cell population (% of total) in Sub-G1 G0/G1, S, and G2/M phases. Results are presented as mean ± SEM (n = 3; *significantly different as compared to the untreated control group; *** (P ≤ 0.001), ** (P ≤ 0.01), and * (P ≤ 0.05)